| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Transcription factor HIVEP2 is suitable for use in Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-2000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
HIVEP2 |
| Gene ID: |
3097 |
| Uniprot ID: |
ZEP2_HUMAN |
| Specificity: |
This antibody detects endogenous levels of HIVEP2 at Human, Mouse, Rat |
| Immunogen: |
Synthesized peptide derived from human HIVEP2 |
| Function | This protein specifically binds to the DNA sequence 5'-GGGACTTTCC-3' which is found in the enhancer elements of numerous viral promoters such as those of SV40, CMV, or HIV1. In addition, related sequences are found in the enhancer elements of a number of cellular promoters, including those of the class I MHC, interleukin-2 receptor, somatostatin receptor II, and interferon-beta genes. It may act in T-cell activation. |
| Protein Name | Transcription Factor Hivep2Human Immunodeficiency Virus Type I Enhancer-Binding Protein 2Hiv-Ep2Mhc-Binding Protein 2Mbp-2 |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Transcription Factor Hivep2 antibodyAnti-Human Immunodeficiency Virus Type I Enhancer-Binding Protein 2 antibodyAnti-Hiv-Ep2 antibodyAnti-Mhc-Binding Protein 2 antibodyAnti-Mbp-2 antibodyAnti-HIVEP2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
